Research Collaborations

We collaborate with many partners in (international) consortia

Add innovative applications and clear time-lines to your proposals:
include a SME in your consortium

Our grant application specialists have years of experience in writing for National and European Commision funding opportunities.
Improve your grant application success rate by partnering with NGS specialists.

Added value

In (inter)national consortia scientific success is not only achieved by merely developing innovative technologies. Reviewing the whole sample chain from organism to data-analysis is just as important. Our collaborators value that GenomeScan scientists provide expert advice how to design the genomics work packages of the project, so that during data-analysis, valid conclusions can be drawn.

Addition of an SME allows to you apply to more grants and can increase the rating of your application. Next to increasing the effectiveness of the work plan, our scientists improve impact sections and can write the commercialization plan. Identification of biomarkers, development of a bioinformatics tools or making a newly developed genetic test available to the scientific community, is often one of the project’s aims. We help to formulate a concise description of the market potential and the planned path to commercialization.

Expertise and a broad portfolio

The GenomeScan portfolio contains a full range of DNA sequencing, gene-expression and epigenetic applications. Depending on your project needs, our scientists can also develop tailored applications. Our skilled bioinformaticians can perform and assist with data-analysis, so you can proceed with the biological interpretation of your cohorts.

Collecting samples for large cohorts can be challenging. Researchers value that we offer robust applications and deliver the results within short time frames. Reach your milestones fast by including our sequencing experts!

Contact us

to explore the possibilities to collaborate in a Horizon2020, COST Action, Marie-Sklodowska-Curie Action, STW
or any other (inter)national grant application program.

Our funded projects


Regeneration through immune modulation. This project aims to induce tissue regeneration in patients with visceral Graft versus Host Disease in a Phase III clinical trial. It will set the standard for treatment of GvHD using mesenchymal stem cell(MSC)-based regenerative therapy.


GenomeScan is an associated partner in the MELGEN Marie Skłodowska-Curie Early Training Network (ETN). The Melanoma Genetics consortium is comprised of the majority of research groups worldwide, who work on the genetics of familial melanoma. GenomeScan will perform genetic research, provide expert advice and give courses for the MC-fellows.


A new Epigenetics project Targeting EPIgetic dysregulation in the brainstem in Alzheimer’s Disease (AD). Previous work performed by GenomeScan and the Maastricht University indicated that (hydroxy)methylation represent critical factors in the pathogenesis of AD. In this project, the partners further analyze the key role of the brainstem, particularly serotonin (5-HT)- and noradrenaline (NA)-specific neurons.


TRANSlational research network for PrOsTate cancer. GenomeScan will contribute to this project by performing microRNA profiling. MicroRNA molecules may be valuable biomarkers and/or key components of the molecular pathways disturbed in PC.


INTernational study for treatment of childhood RElapsed ALL. Clinical trial for treatment of childhood relapsed leukemia. Clinical trial for treatment of childhood relapsed ALL with standard therapy (Epratuzumab), integration of new agents and establishment of standardized diagnostic and research tools. GenomeScan will perform targeted sequencing.


Whole Genome testing (i.e. testing 3Gb of human sequence) will soon be a standard procedure in human genetics. The 3Gb-TEST consortium helps the community to be prepared for this change. We are co-founder and co-chair of this FP7 coordination and support action.


TranCYST is a Marie-Curie training Network focusing on Autosomal Dominant Polycystic Kidney Disease (PKD). We perform molecular and system biology research on PKD mouse models.


The FP7 project “Systems Biology to Identify Molecular Targets for Vascular Disease Treatment” started 2013. Although cardiovascular diseases are the number one killer in the Western world, their molecular causes are still mostly unknown. We are proud to join this search for relevant biomarkers.


A FP7-funded project aimed at developing biocatalysts based on fungal feruloyl esterases and glucuronoyl esterases for production of phenolic fatty- and sugar- esters with antioxidant activity for cosmetic industry. We perform genomics and transcriptomics analysis on various new and known fungal species as contribution to this multidisciplinary consortium.


The second CTMM project performed by our laboratory. We utilize innovative Next Generation Sequencing technology to perform low-pass whole genome, full exome and RNA sequencing of 50 prostate tumors, 30 colorectal adenomas and 30 colorectal carcinomas.


“Clinical and system –omics for the identification of the MOlecular DEterminants of established Chronic Kidney Disease” Is a Marie-Curie research within the FP7 European funding scheme. Our PhD student performs expression profiling on kidney biopsies.


Integrated research on developmental determinants of Aging and Longevity - search for biomarkers determining longevity. We performed Affymetrix microarray analysis and developed assays for (hydroxy)methylation analysis. IDEAL is an FP7-funded consortium.


A project on exposomics. The ‘exposome’ represents the totality of exposures from conception onwards, simultaneously identifying, characterizing and quantifying the exogenous and endogenous exposures and modifiable risk factors that predispose to and predict diseases throughout a person’s life.


This consortium researched melanoma genetics. We performed high-throughput genotyping experiments on melanoma tissues. This project yielded multiple Nature Genetics publications and ended in 2011.


Focused Analysis of Solid Tumor material by single molecule SEQuencing. The project aims to develop assays for mutation detection in FFPE tumor material. We are the network coordinator of this project. The project is funded by AgentschapNL/RVO.


The COST Action BM 1208 draws together researchers of all 8 known human imprinting disorders (IDs) in an interdisciplinary pan-European network for human congenital IDs. We are happy to contribute our knowledge on DNA modification analysis to this consortium (


Long term effects of early nutrition on later health. Our focus lies on detecting Epigenetic variations. We will perform methylation analysis experiments using the Illumina HumanMethylation450K BeadChip. EarlyNutrition is an FP7-funded project.


In 2013 we joined the first prospective study on the pathophysiology of epilepsy. We will sequence the genome and the transcriptome of young patients with tuberous sclerosis before and after the onset of epilepsy (


A Marcie-Curie project aimed at the identification of new genes and their regulators (e.g. microRNAs) that draw cancer cells to colonize bone. Within the Bone Net project, we used the Fluidigm platform for single-cell transcriptome analysis.


Decrease Colorectal Cancer Death - researching copy number variation in rectal carcinoma tumours. We perform genotyping experiments on the Illumina and Fluidigm platforms. The DeCoDe project was initiated in 2008 and is funded by Center for Translational Molecular Medicine (CTMM) a public-private Dutch partnership supporting translational research.

logo-servicexs-grey-pngA GenomeScan brand

ServiceXS is our research department for genetic analyses. Our scientists constantly test and develop technologies and applications to stay one step ahead in genetic testing. We offer a wide range of applications for veterinary, agriculture, microbial and medical research.